

Docket No.

221045US0PCT

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Akira MORIGUCHI, et al.

SERIAL NO:

New US PCT application based on PCT/JP00/06874

GAU:

FILED:

Herewith

EXAMINER:

FOR:

NEW USE

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

#### REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

#### .RELATED CASES

- Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

### **CERTIFICATION**

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

#### **DEPOSIT ACCOUNT**

Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No.

24,618

Surinder Sachar

Registration No.

34,423



Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 10/01)

Form PTO 1449	U.S. DEPARTMENT OF COMMERCE			ATTY DOCKET NO.		SERIAL NO.		
(Modified)		PATENT AND TRADE	EMARK OFFICE	221045US0PCT	New US PCT application based on PCT/JP00/06874			
				APPLICANT				
LIST OF	REFE	RENCES CITED BY APP	LICANT	Akira MORIGUCHI, et al.				
				FILING DATE	GROUP			
				Herewith				
				U.S. PATENT DOCUMENTS				· · ·
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB FILING DATE CLASS IF APPROPRIATE		
	AA	5 945 432	08/31/99	Martin M. BEDNAR et al.				
	AB	5 648 351	07/15/97	John S. KELLY et al.				
	AC							Lis IL.
	AD							
	AE							
		L		DEIGN BATENT BOOKMENTS				
	<del>,</del>	<u>r-</u>	, FO	REIGN PATENT DOCUMENTS				
		DOCUMENT	DATE	COUNTRY		TRANSLATION		LATION
		NUMBER				YES	3	NO
	AF							
	AG							
	АН							
	Al							
	AJ							
	AK							
	AL							
	AM							
		OTHER RE	FERENCES (	Including Author, Title, Date, Pertinen	t Pages, e	tc.)		
	Ė						utic effi	cacy with
	AN⁵	Maeda MASASHI et al.: "FK506 (tacrolimus) as a potential anti-stroke agent (3): Increased therapeutic efficacy with combined treatment of FK506 and recombinant tissue plasminogen activator (rt-PA) in a rat stroke model"  JAPANESE JOURNAL OF PHARMACOLOGY, vol. 82, no. Suppl. 1, page 174P  2000						
	AO	Y. YAGITA et al.: "Effect of immunosuppressant FK506 on ischemia-induced degeneration of hippocampal neurons in gerbils" LIFE SCIENCES, vol. 59, no. 19, pages 1643-1650						
		1996 Thomas J. TUONG et al.: "Neuroprotective FK506 does not alter in vivo nitric oxide production during ischemia and early						
	AP	reperfusion in rats"  STROKE, vol. 30, no. 6, pages 1279-1285  06/99						
		D. BOCHELEN et al.: "Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral						
	AQ	ischemic/reperfusion injury" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 288, no. 2, pages 653-659 02/99						
	AR,	Kim YANG-HEE et al.: "Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator" SCIENCE, vol. 284, no. 5414, pages 647-650 04/23/99						
	AS	M.M. BEDNAR et al.: "Combination tissue plasminogen activator and ticlopidine therapy in a rabbit model of acute thromboembolic research"  NEUROLOGICAL RESEARCH, vol 18, no. 1, pages 45-48 02/01/96						
	AT	BUNDICK et al.: "FK506 as an agonist to induce the inhibition of interleukin 2 production"  TRANSPLANTATION, vol. 53, no. 5, pages 1150-1153  1992  Additional References sheet(s) attached						
Examiner					Date Co	Date Considered		
*Examiner: Ir	nitial if r	reference is considered.	whether or no	t citation is in conformance with MPEP 6	D9; Draw li	ne through	citation	if not in
conformance	and no	ot considered. Include co	ny of this form	with next communication to applicant				